Physician profile
Ryan L Beaver
NPI 1568849156
$1,446.78
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2021: $293 · 2022: $452 · 2023: $350 · 2024: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $471 · Education: $98.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $470.98 |
| Education | $98.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $229.76 | 2022-2024 | Fetroja |
| Abbvie INC. | $219.90 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $142.75 | 2021-2022 | |
| Allergan, INC. | $131.88 | 2019 | |
| Viiv Healthcare Company | $116.03 | 2023-2024 | Cabenuva |
| Smith+Nephew, INC. | $112.94 | 2022-2023 | Collagenase Santyl, Regranex |
| Melinta Therapeutics, LLC | $109.30 | 2022 | |
| Pfizer INC. | $103.11 | 2023 | |
| Astellas Pharma US INC | $79.99 | 2024 | |
| Kci USA, INC. | $57.08 | 2021-2023 | V.A.C. Dermatac, Activ.A.C., Promogran Prisma |
| Lifenet Health | $50.56 | 2023 | |
| Merck Sharp & Dohme LLC | $44.18 | 2023-2024 | Zerbaxa, Recarbrio, Dificid |
| Gilead Sciences, INC. | $25.02 | 2023 | |
| Biogen, INC. | $24.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Beaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.